NovoCure, which markets a wearable electric field device for treating glioblastoma brain cancer, slashed its range and removed insider selling ahead of its upcoming IPO on Thursday. The St Helier, Jersey-based company now plans to raise $176 million by...read more
NovoCure, which markets a wearable electric field device for treating glioblastoma brain cancer, announced terms for its IPO on Monday. The St Helier, Jersey-based company plans to raise $344 million by offering 12.5 million shares (40% insider) at a price...read more
This week saw 8 IPOs raise $1.7 billion. While 5 of the 13 were delayed, the rest averaged 18% return, and all but one ended the week positive. Broader markets continue to rally as the Dow and S&P 500 closed at new record highs and the VIX volatility index...read more
Nevro, which is awaiting approval for an implanted electrical device that treats leg and back pain, raised $126 million by offering 7.0 million shares (vs. 6.25 million originally planned) at $18, above the $15 to $17 range. Nevro will list on the NYSE under the...read more
NovoCure slashes range and removes insider selling ahead of $176 million IPO
NovoCure, which markets a wearable electric field device for treating glioblastoma brain cancer, slashed its range and removed insider selling ahead of its upcoming IPO on Thursday. The St Helier, Jersey-based company now plans to raise $176 million by...read more
The brain cancer backpack: NovoCure sets terms for $344 million IPO
NovoCure, which markets a wearable electric field device for treating glioblastoma brain cancer, announced terms for its IPO on Monday. The St Helier, Jersey-based company plans to raise $344 million by offering 12.5 million shares (40% insider) at a price...read more
US IPO Weekly Recap: 8 companies go public with strong returns as 5 delay IPOs
This week saw 8 IPOs raise $1.7 billion. While 5 of the 13 were delayed, the rest averaged 18% return, and all but one ended the week positive. Broader markets continue to rally as the Dow and S&P 500 closed at new record highs and the VIX volatility index...read more
Nevro prices upsized IPO at $18, above the range
Nevro, which is awaiting approval for an implanted electrical device that treats leg and back pain, raised $126 million by offering 7.0 million shares (vs. 6.25 million originally planned) at $18, above the $15 to $17 range. Nevro will list on the NYSE under the...read more